100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R43AR076265
Award Date
5/1/20
Completion Date
4/30/23
Dollars Obligated
$225K
Overview
Activity
4
Transactions
4
Subawards
Similar Awards
Federal Agency
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
Awardee
Cadenzamed LLC (KY4YSEPMCDZ1)
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Wayne, PA 19087, USA
Update #1
Update #2
TOWARDS COMMERCIALIZATION OF T1P MRI FOR OSTEOARTHRITIS (OA) DIAGNOSIS AND TREATMENT MONITORING
Posted 4/24/20
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
TOWARDS COMMERCIALIZATION OF T1P MRI FOR OSTEOARTHRITIS (OA) DIAGNOSIS AND TREATMENT MONITORING - ABSTRACT OSTEOARTHRITIS (OA) IS A DEBILITATING DISEASE THAT RESULTS IN CARTILAGE LOSS AND PAIN, AND HAS A SIGNIFICANT IMPACT ON MORBIDITY AND HEALTHCARE COSTS WORLDWIDE. THERE IS AN UNMET NEED FOR A THERAPEUTIC INTERVENTION THAT LIMITS THE PROGRESSION OF OA. MANY THERAPEUTIC TARGETS ARE BEING PURSUED BY PHARMACEUTICAL COMPANIES TO DEVELOP SUCCESSFUL DISEASE MODIFYING THERAPY FOR OA. HOWEVER, THE MAJOR IMPEDIMENT IN THE DEVELOPMENT OF EFFECTIVE OA THERAPEUTICS IS THE ABSENCE OF A RELIABLE INDEX FOR MEASURING DISEASE MODIFYING EFFECTS OF DRUG CANDIDATES IN CLINICAL TRIALS. RADIOGRAPHIC MEASURES OF JOINT SPACE NARROWING (JSN), CURRENTLY USED ENDPOINTS IN CLINICAL TRIALS, LACK SENSITIVITY TO SOFT TISSUES AND THUS ARE UNABLE TO DETECT EARLY CARTILAGE ABNORMALITIES. THUS, JSN MAY NOT BE CLINICALLY RELEVANT AS A PRIMARY ENDPOINT FOR MEASURING EFFICACY OF A DISEASE MODIFYING AGENT. THEREFORE, THERE IS A CRITICAL NEED FOR A VALIDATED NONINVASIVE IMAGING BIOMARKER FOR THE EARLY DIAGNOSIS OF OA AND TO MEASURE THE RESPONSE OF A DRUG TO DEVELOP NOVEL THERAPEUTICS TO IMPROVE OA PATIENT CARE AND REDUCE HEALTHCARE COSTS. A T1R MRI METHOD, DEVELOPED AND PATENTED BY DR. REDDY'S GROUP AT THE UNIVERSITY OF PENNSYLVANIA, HAS BEEN SHOWN TO DETECT EARLY CARTILAGE ABNORMALITIES IN OA PATIENTS INCLUDING THE FINDING THAT T1R VALUES ARE ELEVATED IN EARLY, MODERATE AND ADVANCED STAGES OF OA (IN A LIMITED NUMBER OF PATIENTS), WHEN COMPARED WITH CORRESPONDING ASYMPTOMATIC SUBJECTS. HOWEVER, FOR 3D T1R MRI TO BE A VIABLE COMMERCIAL PRODUCT FOR ROUTINE CLINICAL APPLICATIONS, ONE NEEDS TO ADDRESS THE FOLLOWING TWO CHALLENGES: I) THE VARIABILITY OF 3D T1R MRI ACROSS MRI VENDORS; AND II) THE LACK OF VALIDATION OF THE 3D T1R MRI IMAGING BIOMARKER. WE PROPOSE TO DEVELOP A ROBUST CLINICALLY VALIDATED COMMERCIAL 3D T1R MRI PRODUCT FOR ROUTINE CLINICAL DIAGNOSIS OF OA AND FOR MEASURING THE PROGRESSION OF THE DISEASE AND ITS RESPONSE TO THERAPY IN OA CLINICAL TRIALS. TOWARDS THAT GOAL, WE PROPOSE TO ADDRESS THE FIRST CHALLENGE OF COMMERCIALIZATION BY ESTABLISHING THE CLINICALLY RELEVANT REPRODUCIBILITY ERROR IN T1R IN HEALTHY VOLUNTEERS WITHIN AND ACROSS 3T MRI SCANNERS TO GENERATE AN EVIDENCE-BASED FOUNDATION TO MOVE TO PHASE II FOR CLINICAL VALIDATION OF THE BIOMARKER. ONCE THE VARIABILITY OF 3D T1R MRI HAS BEEN ESTABLISHED AT THE END OF THE PROPOSED STUDY, WE WILL ENGAGE, IN PHASE II, TO CLINICALLY VALIDATE 3D T1R MRI IMAGING BIOMARKER USING THE STANDARD OF PRACTICE OF OA DISEASE DIAGNOSIS AND PROGRESSION, KELLGREN-LAWRENCE (KL) GRADE (A GOLD STANDARD), IN A WELL POWERED CLINICAL STUDY. IN ADDITION, WE WILL INITIATE COLLABORATIVE OA CLINICAL TRIALS WITH PHARMA/CRO DURING PHASE II AND WILL BEGIN DISCUSSIONS WITH REGULATORY AGENCIES TO SECURE A CPT CODE FOR 3D T1R MRI FOR EARLY DIAGNOSIS OF OA.
$0
1/11/24
Not listed
TOWARDS COMMERCIALIZATION OF T1P MRI FOR OSTEOARTHRITIS (OA) DIAGNOSIS AND TREATMENT MONITORING - ABSTRACT OSTEOARTHRITIS (OA) IS A DEBILITATING DISEASE THAT RESULTS IN CARTILAGE LOSS AND PAIN, AND HAS A SIGNIFICANT IMPACT ON MORBIDITY AND HEALTHCARE COSTS WORLDWIDE. THERE IS AN UNMET NEED FOR A THERAPEUTIC INTERVENTION THAT LIMITS THE PROGRESSION OF OA. MANY THERAPEUTIC TARGETS ARE BEING PURSUED BY PHARMACEUTICAL COMPANIES TO DEVELOP SUCCESSFUL DISEASE MODIFYING THERAPY FOR OA. HOWEVER, THE MAJOR IMPEDIMENT IN THE DEVELOPMENT OF EFFECTIVE OA THERAPEUTICS IS THE ABSENCE OF A RELIABLE INDEX FOR MEASURING DISEASE MODIFYING EFFECTS OF DRUG CANDIDATES IN CLINICAL TRIALS. RADIOGRAPHIC MEASURES OF JOINT SPACE NARROWING (JSN), CURRENTLY USED ENDPOINTS IN CLINICAL TRIALS, LACK SENSITIVITY TO SOFT TISSUES AND THUS ARE UNABLE TO DETECT EARLY CARTILAGE ABNORMALITIES. THUS, JSN MAY NOT BE CLINICALLY RELEVANT AS A PRIMARY ENDPOINT FOR MEASURING EFFICACY OF A DISEASE MODIFYING AGENT. THEREFORE, THERE IS A CRITICAL NEED FOR A VALIDATED NONINVASIVE IMAGING BIOMARKER FOR THE EARLY DIAGNOSIS OF OA AND TO MEASURE THE RESPONSE OF A DRUG TO DEVELOP NOVEL THERAPEUTICS TO IMPROVE OA PATIENT CARE AND REDUCE HEALTHCARE COSTS. A T1R MRI METHOD, DEVELOPED AND PATENTED BY DR. REDDY'S GROUP AT THE UNIVERSITY OF PENNSYLVANIA, HAS BEEN SHOWN TO DETECT EARLY CARTILAGE ABNORMALITIES IN OA PATIENTS INCLUDING THE FINDING THAT T1 VALUES ARE ELEVATED IN EARLY, MODERATE AND ADVANCED STAGES OF OA (IN A LIMITED NUMBER OF PATIENTS), WHEN COMPARED WITH CORRESPONDING ASYMPTOMATIC SUBJECTS. HOWEVER, FOR 3D T1R MRI TO BE A VIABLE COMMERCIAL PRODUCT FOR ROUTINE CLINICAL APPLICATIONS, ONE NEEDS TO ADDRESS THE FOLLOWING TWO CHALLENGES: I) THE VARIABILITY OF 3D T1R MRI ACROSS MRI VENDORS; AND II) THE LACK OF VALIDATION OF THE 3D T1R MRI IMAGING BIOMARKER. WE PROPOSE TO DEVELOP A ROBUST CLINICALLY VALIDATED COMMERCIAL 3D T1R MRI PRODUCT FOR ROUTINE CLINICAL DIAGNOSIS OF OA AND FOR MEASURING THE PROGRESSION OF THE DISEASE AND ITS RESPONSE TO THERAPY IN OA CLINICAL TRIALS. TOWARDS THAT GOAL, WE PROPOSE TO ADDRESS THE FIRST CHALLENGE OF COMMERCIALIZATION BY ESTABLISHING THE CLINICALLY RELEVANT REPRODUCIBILITY ERROR IN T1 IN HEALTHY VOLUNTEERS WITHIN AND ACROSS 3T MRI SCANNERS TO GENERATE AN EVIDENCE-BASED FOUNDATION TO MOVE TO PHASE II FOR CLINICAL VALIDATION OF THE BIOMARKER. ONCE THE VARIABILITY OF 3D T1R MRI HAS BEEN ESTABLISHED AT THE END OF THE PROPOSED STUDY, WE WILL ENGAGE, IN PHASE II, TO CLINICALLY VALIDATE 3D T1R MRI IMAGING BIOMARKER USING THE STANDARD OF PRACTICE OF OA DISEASE DIAGNOSIS AND PROGRESSION, KELLGREN-LAWRENCE (KL) GRADE (A GOLD STANDARD), IN A WELL POWERED CLINICAL STUDY. IN ADDITION, WE WILL INITIATE COLLABORATIVE OA CLINICAL TRIALS WITH PHARMA/CRO DURING PHASE II AND WILL BEGIN DISCUSSIONS WITH REGULATORY AGENCIES TO SECURE A CPT CODE FOR 3D T1R MRI FOR EARLY DIAGNOSIS OF OA.
$0
3/4/22
Not listed
TOWARDS COMMERCIALIZATION OF T1P MRI FOR OSTEOARTHRITIS (OA) DIAGNOSIS AND TREATMENT MONITORING - ABSTRACT OSTEOARTHRITIS (OA) IS A DEBILITATING DISEASE THAT RESULTS IN CARTILAGE LOSS AND PAIN, AND HAS A SIGNIFICANT IMPACT ON MORBIDITY AND HEALTHCARE COSTS WORLDWIDE. THERE IS AN UNMET NEED FOR A THERAPEUTIC INTERVENTION THAT LIMITS THE PROGRESSION OF OA. MANY THERAPEUTIC TARGETS ARE BEING PURSUED BY PHARMACEUTICAL COMPANIES TO DEVELOP SUCCESSFUL DISEASE MODIFYING THERAPY FOR OA. HOWEVER, THE MAJOR IMPEDIMENT IN THE DEVELOPMENT OF EFFECTIVE OA THERAPEUTICS IS THE ABSENCE OF A RELIABLE INDEX FOR MEASURING DISEASE MODIFYING EFFECTS OF DRUG CANDIDATES IN CLINICAL TRIALS. RADIOGRAPHIC MEASURES OF JOINT SPACE NARROWING (JSN), CURRENTLY USED ENDPOINTS IN CLINICAL TRIALS, LACK SENSITIVITY TO SOFT TISSUES AND THUS ARE UNABLE TO DETECT EARLY CARTILAGE ABNORMALITIES. THUS, JSN MAY NOT BE CLINICALLY RELEVANT AS A PRIMARY ENDPOINT FOR MEASURING EFFICACY OF A DISEASE MODIFYING AGENT. THEREFORE, THERE IS A CRITICAL NEED FOR A VALIDATED NONINVASIVE IMAGING BIOMARKER FOR THE EARLY DIAGNOSIS OF OA AND TO MEASURE THE RESPONSE OF A DRUG TO DEVELOP NOVEL THERAPEUTICS TO IMPROVE OA PATIENT CARE AND REDUCE HEALTHCARE COSTS. A T1R MRI METHOD, DEVELOPED AND PATENTED BY DR. REDDY'S GROUP AT THE UNIVERSITY OF PENNSYLVANIA, HAS BEEN SHOWN TO DETECT EARLY CARTILAGE ABNORMALITIES IN OA PATIENTS INCLUDING THE FINDING THAT T1 VALUES ARE ELEVATED IN EARLY, MODERATE AND ADVANCED STAGES OF OA (IN A LIMITED NUMBER OF PATIENTS), WHEN COMPARED WITH CORRESPONDING ASYMPTOMATIC SUBJECTS. HOWEVER, FOR 3D T1R MRI TO BE A VIABLE COMMERCIAL PRODUCT FOR ROUTINE CLINICAL APPLICATIONS, ONE NEEDS TO ADDRESS THE FOLLOWING TWO CHALLENGES: I) THE VARIABILITY OF 3D T1R MRI ACROSS MRI VENDORS; AND II) THE LACK OF VALIDATION OF THE 3D T1R MRI IMAGING BIOMARKER. WE PROPOSE TO DEVELOP A ROBUST CLINICALLY VALIDATED COMMERCIAL 3D T1R MRI PRODUCT FOR ROUTINE CLINICAL DIAGNOSIS OF OA AND FOR MEASURING THE PROGRESSION OF THE DISEASE AND ITS RESPONSE TO THERAPY IN OA CLINICAL TRIALS. TOWARDS THAT GOAL, WE PROPOSE TO ADDRESS THE FIRST CHALLENGE OF COMMERCIALIZATION BY ESTABLISHING THE CLINICALLY RELEVANT REPRODUCIBILITY ERROR IN T1 IN HEALTHY VOLUNTEERS WITHIN AND ACROSS 3T MRI SCANNERS TO GENERATE AN EVIDENCE-BASED FOUNDATION TO MOVE TO PHASE II FOR CLINICAL VALIDATION OF THE BIOMARKER. ONCE THE VARIABILITY OF 3D T1R MRI HAS BEEN ESTABLISHED AT THE END OF THE PROPOSED STUDY, WE WILL ENGAGE, IN PHASE II, TO CLINICALLY VALIDATE 3D T1R MRI IMAGING BIOMARKER USING THE STANDARD OF PRACTICE OF OA DISEASE DIAGNOSIS AND PROGRESSION, KELLGREN-LAWRENCE (KL) GRADE (A GOLD STANDARD), IN A WELL POWERED CLINICAL STUDY. IN ADDITION, WE WILL INITIATE COLLABORATIVE OA CLINICAL TRIALS WITH PHARMA/CRO DURING PHASE II AND WILL BEGIN DISCUSSIONS WITH REGULATORY AGENCIES TO SECURE A CPT CODE FOR 3D T1R MRI FOR EARLY DIAGNOSIS OF OA.
$0
3/4/22
Not listed
TOWARDS COMMERCIALIZATION OF T1P MRI FOR OSTEOARTHRITIS (OA) DIAGNOSIS AND TREATMENT MONITORING
$225.0k
4/24/20